Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Donor:
This clinical study will evaluate the feasibility of a purified CD34 peripheral blood
progenitor cell (PBPC) transplants in patients with hematological malignancies.
The primary objectives of the study are to evaluate the recipient obtaining donor derived
neutrophil engraftment and the incidence of acute graft versus host disease [GvHD] (grade
III-IV).
Secondary objectives include assessments of recipient having donor derived platelet
engraftment, incidence of graft failure and chronic GvHD, overall and disease free survival,
clinical safety and device performance of the CliniMACS CD34 selection device.